Companies / Ascendis Pharma A/S

Ascendis Pharma A/S

Nasdaq: ASNDCIK 1612042HELLERUPascendispharma.com

Financials · FY2025 · EUR

Revenue€720.13M
Net income€-228.03M
Total debt
Cash€616.04M
Diluted EPS€-3.76
Shares outstanding62.0M

Ownership

62.0M shares outstanding
13.6%10%+ / strategic
Ownership
10%+ / strategic13.57%8,411,581
Institutions92.25%57,172,877
Public float0.00%0

Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.

% of common shares outstanding (single-class filing figure). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 15

View all →
Insider% of sharesShares
Cha AlbertDirector
Holtug LarsDirector
Imani SihamDirector
Jensen Michael WolffEVP, Chief Legal Officer

Institutional holders 308

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
May 26, 2026Bienaime Jean Jacques
Director
BuyOrdinary Shares$47.9K+200
+100.00%
400
<0.01% of shares
low
May 26, 2026Bienaime Jean Jacques
Director
BuyOrdinary Shares$47.2K+200
200
<0.01% of shares
low
May 29, 2026Bienaime Jean Jacques
Director
BuyOrdinary Shares$44.8K+200
+50.00%
600
<0.01% of shares
low
May 29, 2026Bienaime Jean Jacques
Director
BuyOrdinary Shares$44.5K+200
+33.33%
800
<0.01% of shares
low
May 29, 2026Bienaime Jean Jacques
Director
BuyOrdinary Shares$22.4K+100
+12.50%
900
<0.01% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Westfield Capital Management Company, L.P.Passive13G/A5,185,696
Artisan Partners Asset Management Inc.Passive13G/A3,225,885
Janus Henderson Group PLCPassive13G/A

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ASND04351P101